ArticleFrontiers in cell and developmental biology2026
Rare variants of
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Recurrent spontaneous abortion (RSA) is associated with embryonic chromosomal abnormalities, yet the maternal genetic factors predisposing to the production of aneuploid gametes remain incompletely understood. Identifying germline variants that disrupt meiotic chromosome segregation may elucidate the genetic etiology of RSA. Methods: Peripheral blood DNA was collected from 100 RSA patients for whom aneuploidy of embryonic origin had been confirmed in prior miscarriage specimens, and whole-exome sequencing (WES) was performed. Rare missense variants in candidate meiotic genes were identified and prioritized for functional analysis. The effect of GPSM2 loss-of-function was modeled via siRNA-mediated knockdown in germ cell lines, and meiotic progression, ploidy outcomes, and spindle-associated protein localization were assessed in vitro and in vivo. Results: Two patients harbored rare heterozygous missense point mutations in GPSM2 (G protein signaling modulator 2). GPSM2 knockdown resulted in a marked increase in diploid spermatocytes (NC: 10.6% vs. GPSM2-siRNA: 53.8%) and a corresponding decrease in haploid spermatids (NC: 57.8% vs. GPSM2-siRNA: 5.49%), indicating failure of the first meiotic division, while earlier spermatogenic stages remained unaffected. Mechanistically, GPSM2 was found to interact with the nuclear mitotic apparatus (NUMA) protein; upon GPSM2 depletion, chromosome separation was arrested at metaphase in GC-2 cells, and NUMA failed to localize to the spindle poles. Discussion: These findings suggest that rare GPSM2 missense mutations predicted to impair gene function may compromise first meiotic chromosome segregation through disruption of the GPSM2-NUMA interaction at the spindle pole, thereby predisposing carriers to produce aneuploid germ cells. Fertilization of such aneuploid gametes would yield chromosomally abnormal embryos, providing a mechanistic basis for RSA in these patients. However, definitive causal attribution awaits direct functional characterization of the specific missense variants identified, as the current study employed siRNA-mediated knockdown as a surrogate loss-of-function model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.